# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Goldman Sachs analyst David Roman initiates coverage on Baxter Intl (NYSE:BAX) with a Neutral rating and announces Price Tar...
Citigroup analyst Joanne Wuensch maintains Baxter Intl (NYSE:BAX) with a Neutral and lowers the price target from $44 to $38.
Investors urge Fresenius SE to clarify its strategic plans for Fresenius Medical Care after recent deconsolidation. Despite hol...
Clinolipid provides calories and essential fatty acids for parenteral nutritionExpanded indication demonstrates Baxter's co...